ARS Pharmaceuticals Stock (NASDAQ:SPRY)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$10.44

52W Range

$6.66 - $18.90

50D Avg

$9.38

200D Avg

$12.81

Market Cap

$1.10B

Avg Vol (3M)

$2.28M

Beta

0.80

Div Yield

-

SPRY Company Profile

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

155

IPO Date

Dec 04, 2020

Website

SPRY Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 24
Product	$7.25M

Fiscal year ends in Dec 24 | Currency in USD

SPRY Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	$89.15M	$30.00K	$1.32M
Operating Income	$-3.08M	$-67.52M	$-35.52M
Net Income	$8.00M	$-54.37M	$-33.99M
EBITDA	$-3.08M	$-67.45M	$-35.52M
Basic EPS	$0.08	$-0.57	$-0.85
Diluted EPS	$0.08	$-0.57	$-0.85

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q3 25Nov 10, 25 | 8:30 AM

Q2 25Aug 13, 25 | 8:30 AM

Q1 25May 14, 25 | 8:30 AM

Peer Comparison

Ticker	Company
NBTX	Nanobiotix S.A.
PVLA	Palvella Therapeutics, Inc.
KURA	Kura Oncology, Inc.
ABUS	Arbutus Biopharma Corporation
RZLT	Rezolute, Inc.
GHRS	GH Research PLC
TYRA	Tyra Biosciences, Inc.
PROK	ProKidney Corp.
SVRA	Savara Inc.
LENZ	LENZ Therapeutics, Inc.